US Stock MarketDetailed Quotes

JAZZ Jazz Pharmaceuticals

Watchlist

124.340
-2.330-1.84%

Close Nov 25 16:00 ET

126.200
+1.860+1.50%

Post 17:16 ET

7.52BMarket Cap17.61P/E (TTM)

Jazz Pharmaceuticals Stock Forum

Stock_Drift

Nov 20 18:32

$Jazz Pharmaceuticals (JAZZ.US)$

10xStockPicks

Oct 24 07:55

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable

Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 million Americans take statin drugs, we see continued prescription growth & expect over 5...

+20

Stock_Drift

Sep 16 06:45

$Jazz Pharmaceuticals (JAZZ.US)$

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Moomoo AI

Mar 27 06:55

Despite Jazz Pharmaceuticals' revenue growth and profitability, its share price drop may signal unresolved issues. The long-term share price weakness could be a bad sign, yet contrarian investors might see a potential turnaround opportunity.

5.0% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Jazz Pharmaceuticals (NASDAQ:JAZZ) Shareholders Over That Period

Moomoo AI

Feb 29 08:59

The low ROE and high debt usage of Jazz Pharmaceuticals make it a less exciting investment at the moment. The company's performance could be impacted if it was unable to borrow as easily in changing credit markets.

Can Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) Improve Its Returns?

Moomoo AI

Jan 7 07:45

Jazz Pharmaceuticals' low P/S ratio is due to slower revenue growth compared to industry trend, leading to discomfort amongst shareholders and stock devaluation. Persisting sluggish growth may decrease P/S ratio even further unless fortunes change.

Jazz Pharmaceuticals Plc's (NASDAQ:JAZZ) Shares Lagging The Industry But So Is The Business

Moomoo AI

Oct 20, 2023 12:59

Analyst Joon Lee supports the potential split of Jazz's businesses given its growing oncology unit and competitive CNS franchise, valuing Jazz at $200 per share. Alternatively, Jason Gerberry suggests selling the oncology unit and focusing on CNS or spin-off maybe more likely than a total sale, with a 'buy' rating and $217 price target remaining.